Global Active Pharmaceutical Ingredients Market 2024-2028

The active pharmaceutical ingredients market is forecasted to grow by USD 86.47 bn during 2023-2028, accelerating at a CAGR of 6.73% during the forecast period. The report on the active pharmaceutical ingredients market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by evolving api manufacturing scenario in developing scenario, increasing number of type II drug master files (DMF), and growing need to focus on core competencies.

Market Scope
Base Year	2023
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	6.24%
CAGR	6.73%
Incremental Value	$86.47bn

Technavio's active pharmaceutical ingredients market is segmented as below:

By Manufacturing Type

Captive APIs
Contract APIs

By Type

Innovative APIs
Generic APIs

By Geographical Landscape

Asia
North America
Europe
Rest of World (ROW)

This study identifies the paradigm shift in API manufacturing as one of the prime reasons driving the active pharmaceutical ingredients market growth during the next few years. Also, increasing patent exercises and increasing geriatric population will lead to sizable demand in the market.

The report on the active pharmaceutical ingredients market covers the following areas:

Active pharmaceutical ingredients market sizing
Active pharmaceutical ingredients market forecast
Active pharmaceutical ingredients market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading active pharmaceutical ingredients market vendors that include AbbVie Inc., Amneal Pharmaceuticals Inc., Apotex Inc., Aurobindo Pharma Ltd., Cadila Pharmaceuticals Ltd., Cambrex Corp., Cipla Ltd., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Indena S.p.A., INTERNATIONAL CHEMICAL INVESTORS S.E., Koninklijke DSM NV, Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc.. Also, the active pharmaceutical ingredients market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR40608

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Manufacturing Type
Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global active pharmaceutical ingredients market (API) 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global active pharmaceutical ingredients market (API) 2018 - 2022 ($ billion)
4.2 Manufacturing Type Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Manufacturing Type Segment 2018 - 2022 ($ billion)
4.3 Type Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Type Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Manufacturing Type

6.1 Market segments
Exhibit 30: Chart on Manufacturing Type - Market share 2023-2028 (%)
Exhibit 31: Data Table on Manufacturing Type - Market share 2023-2028 (%)
6.2 Comparison by Manufacturing Type
Exhibit 32: Chart on Comparison by Manufacturing Type
Exhibit 33: Data Table on Comparison by Manufacturing Type
6.3 Captive APIs - Market size and forecast 2023-2028
Exhibit 34: Chart on Captive APIs - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Captive APIs - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Captive APIs - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Captive APIs - Year-over-year growth 2023-2028 (%)
6.4 Contract APIs - Market size and forecast 2023-2028
Exhibit 38: Chart on Contract APIs - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Contract APIs - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Contract APIs - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Contract APIs - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Manufacturing Type
Exhibit 42: Market opportunity by Manufacturing Type ($ billion)
Exhibit 43: Data Table on Market opportunity by Manufacturing Type ($ billion)

7 Market Segmentation by Type

7.1 Market segments
Exhibit 44: Chart on Type - Market share 2023-2028 (%)
Exhibit 45: Data Table on Type - Market share 2023-2028 (%)
7.2 Comparison by Type
Exhibit 46: Chart on Comparison by Type
Exhibit 47: Data Table on Comparison by Type
7.3 Innovative APIs - Market size and forecast 2023-2028
Exhibit 48: Chart on Innovative APIs - Market size and forecast 2023-2028 ($ billion)
Exhibit 49: Data Table on Innovative APIs - Market size and forecast 2023-2028 ($ billion)
Exhibit 50: Chart on Innovative APIs - Year-over-year growth 2023-2028 (%)
Exhibit 51: Data Table on Innovative APIs - Year-over-year growth 2023-2028 (%)
7.4 Generic APIs - Market size and forecast 2023-2028
Exhibit 52: Chart on Generic APIs - Market size and forecast 2023-2028 ($ billion)
Exhibit 53: Data Table on Generic APIs - Market size and forecast 2023-2028 ($ billion)
Exhibit 54: Chart on Generic APIs - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Generic APIs - Year-over-year growth 2023-2028 (%)
7.5 Market opportunity by Type
Exhibit 56: Market opportunity by Type ($ billion)
Exhibit 57: Data Table on Market opportunity by Type ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 58: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 59: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 60: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 61: Chart on Geographic comparison
Exhibit 62: Data Table on Geographic comparison
9.3 Asia - Market size and forecast 2023-2028
Exhibit 63: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 64: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 65: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 66: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.4 North America - Market size and forecast 2023-2028
Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.5 Europe - Market size and forecast 2023-2028
Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 75: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 China - Market size and forecast 2023-2028
Exhibit 79: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on China - Year-over-year growth 2023-2028 (%)
9.8 US - Market size and forecast 2023-2028
Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
9.9 India - Market size and forecast 2023-2028
Exhibit 87: Chart on India - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on India - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on India - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on India - Year-over-year growth 2023-2028 (%)
9.10 Japan - Market size and forecast 2023-2028
Exhibit 91: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on Japan - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Japan - Year-over-year growth 2023-2028 (%)
9.11 Germany - Market size and forecast 2023-2028
Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 99: Market opportunity By Geographical Landscape ($ billion)
Exhibit 100: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 101: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 102: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 103: Overview on factors of disruption
11.4 Industry risks
Exhibit 104: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 105: Vendors covered
12.2 Market positioning of vendors
Exhibit 106: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 107: AbbVie Inc. - Overview
Exhibit 108: AbbVie Inc. - Product / Service
Exhibit 109: AbbVie Inc. - Key news
Exhibit 110: AbbVie Inc. - Key offerings
12.4 Amneal Pharmaceuticals Inc.
Exhibit 111: Amneal Pharmaceuticals Inc. - Overview
Exhibit 112: Amneal Pharmaceuticals Inc. - Business segments
Exhibit 113: Amneal Pharmaceuticals Inc. - Key news
Exhibit 114: Amneal Pharmaceuticals Inc. - Key offerings
Exhibit 115: Amneal Pharmaceuticals Inc. - Segment focus
12.5 Aurobindo Pharma Ltd.
Exhibit 116: Aurobindo Pharma Ltd. - Overview
Exhibit 117: Aurobindo Pharma Ltd. - Product / Service
Exhibit 118: Aurobindo Pharma Ltd. - Key offerings
12.6 Cadila Pharmaceuticals Ltd.
Exhibit 119: Cadila Pharmaceuticals Ltd. - Overview
Exhibit 120: Cadila Pharmaceuticals Ltd. - Product / Service
Exhibit 121: Cadila Pharmaceuticals Ltd. - Key offerings
12.7 Cipla Ltd.
Exhibit 122: Cipla Ltd. - Overview
Exhibit 123: Cipla Ltd. - Business segments
Exhibit 124: Cipla Ltd. - Key news
Exhibit 125: Cipla Ltd. - Key offerings
Exhibit 126: Cipla Ltd. - Segment focus
12.8 Dr Reddys Laboratories Ltd.
Exhibit 127: Dr Reddys Laboratories Ltd. - Overview
Exhibit 128: Dr Reddys Laboratories Ltd. - Business segments
Exhibit 129: Dr Reddys Laboratories Ltd. - Key offerings
Exhibit 130: Dr Reddys Laboratories Ltd. - Segment focus
12.9 GlaxoSmithKline Plc
Exhibit 131: GlaxoSmithKline Plc - Overview
Exhibit 132: GlaxoSmithKline Plc - Business segments
Exhibit 133: GlaxoSmithKline Plc - Key news
Exhibit 134: GlaxoSmithKline Plc - Key offerings
Exhibit 135: GlaxoSmithKline Plc - Segment focus
12.10 Koninklijke DSM NV
Exhibit 136: Koninklijke DSM NV - Overview
Exhibit 137: Koninklijke DSM NV - Business segments
Exhibit 138: Koninklijke DSM NV - Key news
Exhibit 139: Koninklijke DSM NV - Key offerings
Exhibit 140: Koninklijke DSM NV - Segment focus
12.11 Lupin Ltd.
Exhibit 141: Lupin Ltd. - Overview
Exhibit 142: Lupin Ltd. - Product / Service
Exhibit 143: Lupin Ltd. - Key news
Exhibit 144: Lupin Ltd. - Key offerings
12.12 Novartis AG
Exhibit 145: Novartis AG - Overview
Exhibit 146: Novartis AG - Business segments
Exhibit 147: Novartis AG - Key offerings
Exhibit 148: Novartis AG - Segment focus
12.13 Pfizer Inc.
Exhibit 149: Pfizer Inc. - Overview
Exhibit 150: Pfizer Inc. - Product / Service
Exhibit 151: Pfizer Inc. - Key news
Exhibit 152: Pfizer Inc. - Key offerings
12.14 Sanofi SA
Exhibit 153: Sanofi SA - Overview
Exhibit 154: Sanofi SA - Business segments
Exhibit 155: Sanofi SA - Key news
Exhibit 156: Sanofi SA - Key offerings
Exhibit 157: Sanofi SA - Segment focus
12.15 Sun Pharmaceutical Industries Ltd.
Exhibit 158: Sun Pharmaceutical Industries Ltd. - Overview
Exhibit 159: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibit 160: Sun Pharmaceutical Industries Ltd. - Key offerings
12.16 Teva Pharmaceutical Industries Ltd.
Exhibit 161: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 162: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 163: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 164: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 165: Teva Pharmaceutical Industries Ltd. - Segment focus
12.17 Viatris Inc.
Exhibit 166: Viatris Inc. - Overview
Exhibit 167: Viatris Inc. - Business segments
Exhibit 168: Viatris Inc. - Key news
Exhibit 169: Viatris Inc. - Key offerings
Exhibit 170: Viatris Inc. - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 171: Inclusions checklist
Exhibit 172: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 173: Currency conversion rates for US$
13.4 Research methodology
Exhibit 174: Research methodology
Exhibit 175: Validation techniques employed for market sizing
Exhibit 176: Information sources
13.5 List of abbreviations
Exhibit 177: List of abbreviations